137975-18-9

Basic information

• Product Name: (4-AMINOPHENYL)[3,4-DIHYDRO-1(2H)-QUINOLINYL]-METHANONE
• Synonyms: (4-AMINOPHENYL)[3,4-DIHYDRO-1(2H)-QUINOLINYL]-METHANONE;4-(3,4-dihydro-1(2H)-quinolinylcarbonyl)aniline;(4-aminophenyl)(3,4-dihydroquinolin-1(2H)-yl)methanone
• CAS NO: 137975-18-9
• Molecular Formula: C₁₆H₁₆N₂O
• Molecular Weight: 252.31104
• Mol File: 137975-18-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-AMINOPHENYL)[3,4-DIHYDRO-1(2H)-QUINOLINYL]-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-AMINOPHENYL)[3,4-DIHYDRO-1(2H)-QUINOLINYL]-METHANONE(137975-18-9)
• EPA Substance Registry System: (4-AMINOPHENYL)[3,4-DIHYDRO-1(2H)-QUINOLINYL]-METHANONE(137975-18-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 137975-18-9(Hazardous Substances Data)

Usage

Description

(4-AMINOPHENYL)[3,4-DIHYDRO-1(2H)-QUINOLINYL]-METHANONE, also known as DHAQD, is a quinoline-based chemical compound with potential pharmaceutical properties. It has been studied for its anti-cancer and anti-inflammatory effects, exhibiting cytotoxicity against cancer cells and inhibiting tumor growth. DHAQD also shows promise in treating inflammatory conditions due to its anti-inflammatory properties.

Uses

Used in Oncology:
DHAQD is used as an anti-cancer agent for its cytotoxic effects on cancer cells, which can help inhibit tumor growth. It has been studied for its potential use in treating various types of cancer.
Used in Inflammation Treatment:
DHAQD is used as an anti-inflammatory agent for its ability to reduce inflammation. It has been investigated for its potential in treating various inflammatory conditions, offering a promising therapeutic option for patients suffering from such ailments.

Upstream product

• 137975-17-8 1-(4-nitrobenzoyl)-1,2,3,4-tetrahydroquinoline 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 122-04-3 4-nitro-benzoyl chloride 

Relevant articles and documents

Synthesis and characterization of orally active nonpeptide vasopressin V2 receptor antagonists

The present study was undertaken to evaluate whether a novel series of 2,6-diaza-5-oxobicyclo[5.4.0]undeca-1(7),8,10-triene derivatives exhibited antagonistic activity for vasopressin V1 and V2 receptors. Most of these compounds were

BENZOHETEROCYCLIC COMPOUNDS

Novel benzoheterocyclic compounds of the formula: STR1 wherein R. sup.1 is H, halogen, alkyl, optionally substituted amino, alkoxy; R 2 is H, halogen, alkoxy, phenyialkoxy, OH, alkyl, optionally substituted amino, carbamoyl-alkoxy, optionally substituted